Clinical Trial Update: Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating SCA-136 in subjects with acute exacerbations of schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SCA-136

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED